Day 1 Recap: Fall Clinical 2024

Author(s):

Kaitlyn Bader, Assistant Managing Editor

Key Takeaways

The conference highlights advancements in dermatology, focusing on disease states, therapeutic options, and new clinical data.
Discussions include new topical therapeutics like ruxolitinib and tapinarof, expanding treatment options.
Alternatives to systemic corticosteroids for atopic dermatitis are explored, emphasizing improved patient care.
Dermatology Times Editorial Advisory Board members contribute valuable insights and expertise.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Previewing the 2024 Fall Clinical Dermatology Conference: What to Expect

The conference aimed at providing dermatology clinicians with the latest in the specialty begins today in Las Vegas, Nevada.

POLL: What Topics Are You Looking Forward to at Fall Clinical 2024?

Share with us the topics you want to learn more about at Fall Clinical.

Gearing Up for Fall Clinical 2024 With Raj Chovatiya, MD, PhD

The conference will feature presentations on a number of disease states, therapeutic options, and new clinical data.

Previewing Editorial Advisory Board Member Sessions at Fall Clinical 2024

Among the many sessions to be held at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

The Latest in Dermatology With James Del Rosso, DO: Part 1

Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.

'Stop Writing Systemic Corticosteroids for Atopic Dermatitis': Expanding the Toolkit for AD

Clinicians presented a panel-style session at Fall Clinical, touching on the drawbacks of topical steroid use and alternatives in AD patients.

To view all conference coverage from Fall Clinical 2024, click here.